Medical devices company CAS Medical Systems Inc. (CASM) Wednesday said it received U.S. Food and Drug Administration or FDA 510(k) clearance for its next-generation FORE-SIGHT ELITE Absolute Tissue Oximeter. The company said the device was cleared to provide absolute cerebral oxygenation levels in adult and transitional adolescent patients weighing 40 kilograms or more and is expected to be widely available to customers in the fourth quarter of 2013.
Commenting on the development, Thomas Patton, CEO of CASMED said, "This cutting-edge product exceeds the high levels of accuracy established with our current FORE-SIGHT monitor and will further empower clinicians to protect the brain and enhance patient safety. In addition, this new monitor will afford us the opportunity to lower our cost of goods, expand distribution around the world, and provide an OEM solution to strategic partners."
For comments and feedback: editorial@rttnews.com